Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 8, 2006, Pages 832-836

  Miller, Antonius A ^a,e   Case, Doug ^a   Atkins, James N ^b   Giguere, Jeffrey K ^c   Bearden, James D ^d  

^a WAKE FOREST UNIVERSITY   (United States)

^b Southeast Cancer Control Consortium   (United States)

^c Cancer Centers of the Carolinas   (United States)

^d Gibbs Cancer Center   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Irinotecan; Non small cell lung cancer; Phase II; Thalidomide

Indexed keywords

ATROPINE; CARBOPLATIN; DEXAMETHASONE; GRANISETRON; IRINOTECAN; ONDANSETRON; PALONOSETRON; THALIDOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; MORTALITY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; THALIDOMIDE;

EID: 34248343502     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200610000-00012     Document Type: Article

References (22)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA - Cancer J Clin 2006;55:10-30.
2. Travis WD, Travis LB, Percy C, et al. Lung cancer incidence and survival by histologic type. Cancer 1995;75:191-199.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98.
4. Langer CL. Irinotecan in advanced lung cancer: Focus on North American trials. Oncology 2004;18(Suppl 7):17-28.
5. Natale RB, Socinski M, Sandler A, et al. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. Oncology 2000;7(Suppl 7):29-34.
6. Fukuda M, Oka M, Soda H, et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 1999;5:3963.
7. Mukohara T, Takeda K, Miyazaki M, et al. Phase II study of irinotecan (CPT-11) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:534a.
8. D'Amato M, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994;91:4082-4085.
9. Brem H, Gresser I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surgery 1993;28:1253-1257.
10. Minchinton A, Fryer K, Wendt K, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-343.
11. Teicher B, Sotomayor E, Huang Z. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Research 1992;52:6702-6704.
12. Sampaio E, Sarno E, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991;173:699-703.
13. Tavares J, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor alpha production by human alveolar macrophages. Respiratory Medicine 1997;91:31-39.
14. Merchant JJ, Kim KM, Mehta MP, et al. Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non-small lung cancer. Clin Lung Cancer 2000;2:48-52.
15. Govindarajan R, Heaton KM, Broadwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000;356:566.
16. Marriott JB, Muller G, Dalgleish A. Thalidomide as an emerging immunotherapeutic agent. Immunol Today. 1999;20:538-540.
17. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
18. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidencebased, clinical practice guidelines. J Clin Oncol 2000;18:3558-3585.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205216.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989;10:1-10.
21. Sandler AB. Targeting angiogenesis in lung cancer. Semin Oncol 2006;32(Suppl 10):S16-S22.
22. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 2006;23(Suppl 16):1090S.